LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
LFCR$6.370.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Accrued expenses and other current liabilities
- Accrued expenses and other current liabilities
The following table presents the components of accrued expenses and other current liabilities:
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Accrued compensation | $4,473 | $4,548 |
| Contract liabilities | 3,177 | 3,018 |
| Contract liabilities, related party | 1,482 | 5,642 |
| Accrued customer passthrough expenditures | 1,409 | 258 |
| Accrued professional fees | 1,063 | 1,444 |
| Current portion of debt, related party | 773 | 773 |
| Current portion of debt | 205 | 181 |
| Other | 871 | 1,498 |
| Accrued expenses and other current liabilities | $13,453 | $17,362 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.